The European Medicines Agency (EMA) has granted approval for the use of baricitinib, an oral selective Janus kinase 1 (JAK1) and Janus kinase 2 (JAK 2) inhibitor (Figure 3b), in adult patients with AD who are suitable candidates for biologics. This evidence concerns the gene JAK1 and Alzheimer disease.